Printer Friendly

ROBERTS PHARMACEUTICALS TO ACQUIRE FOUR WYETH LABORATORIES PRODUCT LINES FOR U.K. AND IRISH MARKETS

 ROBERTS PHARMACEUTICALS TO ACQUIRE FOUR WYETH LABORATORIES
 PRODUCT LINES FOR U.K. AND IRISH MARKETS
 EATONTOWN, N.J., Dec. 26 /PRNewswire/ -- In an announcement made simultaneously in the U.S. and the United Kingdom, Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced the completion of an agreement in principle with Wyeth Laboratories - U.K., a subsidiary of American Home Products Corporation, which provides for the acquisition by Roberts of four approved and marketed prescription pharmaceuticals. These products include MEPTID(R) (analgesic), BARATOL(R) (hypertension and peripheral circulatory disorders), ISORDIL(R) (anti-anginal agent) and HRF (ob/gyn). The four products are approved and sold in the U.K. and Ireland. Roberts wholly owned U.K. subsidiary, Monmouth Pharmaceuticals, currently promotes its products through the efforts of 30 contracted sales representatives in the U.K. and 8 representatives in Ireland. Wyeth will continue to manufacture and distribute the products for Monmouth for a specific time period. Financial terms of the transaction were not disclosed.
 Roberts Chairman and CEO Dr. Robert A. Vukovich stated, "The acquisition of the four product lines and their ongoing sales accelerates our timetable for achieving our growth objectives and further enhance the continuing evolution of Roberts into a fully integrated pharmaceutical company."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad. Monmouth Pharmaceuticals markets a line of human pharmaceuticals in the United Kingdom, Republic of Ireland, and the Benelux countries. Monmouth's product line includes MIDON(R), for hypotension, FURACINE(R), for burn wounds, BETADUR(R), beta blocker, ISOMIDE(R), anti-arrhythmic, and CAPRIN(R), analgesic.
 -0- 12/26/91
 /CONTACT: Anthony Maris of Roberts Pharmaceutical, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: TNM


KD-SM -- NY007 -- 5274 12/26/91 11:41 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 26, 1991
Words:336
Previous Article:SEVERN TRENT ANNOUNCES JOINT VENTURE WITH TETRA TECHNOLOGIES
Next Article:EPA APPROVES NEW JERSEY'S PROGRAM TO PROTECT GROUNDWATER USED IN PUBLIC DRINKING WATER SUPPLIES
Topics:


Related Articles
SYNTEX RECEIVES APPROVAL FOR ADDITIONAL TORADOL IM SYRINGE SUPPLIER
WYETH-AYERST LABORATORIES AND THE LIPOSOME COMPANY ANNOUNCE FLU VACCINE AGREEMENT
BURROUGHS WELLCOME CO. AND WYETH-AYERST TO CO-PROMOTE NEW TREATMENT FOR CHICKENPOX
WYETH-AYERST AND PANLABS SIGN RESEARCH COLLABORATION
WYETH-AYERST AND OPHIDIAN PHARMACEUTICALS TO DEVELOP IMPROVED ANTIDOTES FOR POISONOUS SNAKEBITE
AFFYMAX N.V. ANNOUNCES STRATEGIC ALLIANCE WITH AMERICAN HOME PRODUCTS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES UK/ROI ACQUISITION OF PRESCRIPTION PRODUCT MAXOLON FROM SMITHKLINE BEECHAM
ROBERTS PHARMACEUTICAL CORPORATION TO ACQUIRE UK DRUG FOR IRRITABLE BOWEL SYNDROME
Agreement Between Wyeth-Ayerst Laboratories And Elan Pharmaceutical Will Expand Treatment Options for Americans Suffering from Arthritis Pain
American Home Products and King Pharmaceuticals Finalize Co-Promotion Arrangement for Altace(R).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters